Purple Biotech fortifies NT219 patent protection

Purple Biotech announced that the China National Intellectual Property Administration, CNIPA, has granted a new patent for maintaining a pharmaceutical composition of NT219 in its active form. The new patent protects the method which prevents the conversion of NT219 from its active form to a less active form and supports maintenance of the active form during manufacturing, storage and handling until administered to the patient. The new patent granted in China expands Purple Biotech’s patent protection for NT219 in China. The drug was previously issued patent in China that relates to the combinations of NT219 with various anti-cancer agents. “Expanding patent protection for NT219’s composition is strategic for Purple Biotech and we believe that the grant of this new patent marks another step forward in our global intellectual property strategy. China is a large and important market opportunity for us, and strengthening our patent coverage improves our competitive positioning in this territory,” stated Purple Biotech CEO, Gil Efron.